May 8, 2026 02:30AM
May 8, 2026 02:30AM
Mar 20, 2026 12:13PM
Mar 20, 2026 12:05PM
Feb 9, 2026 09:46AM
Feb 9, 2026 06:37AM
Feb 4, 2026 07:30AM BIOGEN publishes study results for high-dose nusinersen in Nature Medicine
Feb 4, 2026 07:30AM
Jan 25, 2026 11:52PM
Jan 25, 2026 06:30PM
Jan 25, 2026 06:30PM
Nov 26, 2025 06:03AM
Nov 25, 2025 07:31AM
Nov 25, 2025 07:30AM Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's
Oct 31, 2025 03:37AM
Jul 31, 2025 03:14PM
Jul 30, 2025 11:00AM
Jul 30, 2025 11:00AM
Jul 30, 2025 11:00AM
Jul 30, 2025 09:00AM
Jul 30, 2025 09:00AM New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
Jul 30, 2025 08:07AM
Jul 20, 2025 08:00PM
Jun 13, 2025 11:43AM
May 15, 2025 10:47AM
Feb 13, 2025 07:39AM
Jan 26, 2025 06:54PM
Jan 26, 2025 06:33PM FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Jan 26, 2025 06:30PM
Jan 13, 2025 07:03PM
Dec 11, 2024 09:44AM
Oct 31, 2024 08:03PM
Aug 6, 2024 06:46AM
Jun 9, 2024 10:13PM
Jun 9, 2024 07:37PM FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Jun 9, 2024 07:30PM
Jun 12, 2023 05:30AM
Jun 9, 2023 06:45PM
Jun 1, 2023 12:55PM
Jun 1, 2023 08:56AM
May 1, 2023 08:43AM
Apr 26, 2023 03:16PM RBC Capital on Biogen (BIIB): 'CMS Makes It Clear - Leqembi Will Be Broadly Reimbursed - Should Reduce Overhang'
Apr 25, 2023 07:52AM
Mar 31, 2023 05:50AM
Mar 30, 2023 07:31PM
Mar 30, 2023 07:30PM
Mar 30, 2023 07:30PM
Mar 30, 2023 07:30PM
Mar 22, 2023 08:31PM Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
Mar 22, 2023 08:31PM

15,439 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All